Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability
An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results for Alterity.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
BJT | what am i not seeing here? | 04/02/23 | 3 | 473 | |||
|
|||||||
BJT | astro boy | 14/08/09 | 8 | 6.1K | |||
|
|||||||
BJT | article 26 july 2009 | 27/07/09 | 0 | 1.1K | |||
|
|||||||
BJT | Ann: Amendments to the Constitution - name change | 23/07/09 | 0 | 1.4K | |||
|
|||||||
BJT | Ann: BJT changes name to Astro Japan Property Tru | 23/07/09 | 0 | 1.5K | |||
|
|||||||
BJT | 13.3% decrease in portfolio value | 21/07/09 | 7 | 2.4K | |||
|
|||||||
BJT | Ann: Ceasing to be a substantial holder | 20/07/09 | 0 | 1.4K | |||
|
|||||||
BJT | Ann: June 2009 Property Revaluations | 20/07/09 | 0 | 1.5K | |||
|
See All Discussions